DCIS is a non-invasive or pre-invasive breast cancer, meaning the cancer cells are confined to the milk ducts and haven’t ...

Antibody–siRNA conjugates (ARCs) are a type of promising drug modalities for cancer therapy. However, initial reports of ARCs present the gene knockdown effect only in limited tissues (e.g., muscles) ...

Bemarituzumab targets FGFR2b, which has been found to be overexpressed in approximately 30% of patients with non-HER2 positive gastric cancer.

The update strengthens IBTROZI's position as a next-generation treatment in a rare, aggressive lung cancer that often spreads ...

Breast cancer remains the ... you to new people and give you a positive perspective on life. Side effects from treatment may ...

US FDA clears Iksuda Therapeutics’ IND application for IKS014: New Castle, England Wednesday, July 2, 2025, 15:00 Hrs [IST] Iksuda Therapeutics, a clinical stage and UK-based bi ...

With an FDA IND clearance, the firm will test IKS014 as an alternative for HER2-positive solid tumor patients in the US who have relapsed on other therapies.

Targeted Oncology connects oncology professionals with updates on immunotherapy, biomarkers, cancer pathways, and targeted ...

Iksuda Therapeutics (Iksuda), the developer of class-leading antibody drug conjugates (ADCs) with clinically validated tumour-selective payload release formats, today announces that the U.S. Food and ...

Researchers tested more than 65,000 patients with more than 30 solid tumor types and found the rate of HER2 positivity was about 3%.

The official results of the BRACELET-01 (PrECOG 0113) trial have been published in Clinical Cancer Research, detailing the safety and efficacy of pelareorep, an investigational oncolytic virus ...